跳至主要内容
临床试验/NL-OMON22434
NL-OMON22434招募中不适用

Electronic nose for breath analysis after curative Surgery to detect distant metastases or locoregional recurrence of colon cancer

•The ‘Medisch Specialistisch Bedrijf’(MSB) of Isala has invested in The eNose Company, Zutphen, The Netherlands. The researchers have received a grant from the Innovation & Science fund Isala. •The eNose Company invests by making the eNose devices, disposable mouthpieces and analysis of the breath tests available.0 个研究点目标入组 1,184 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
1,184

研究概览

简要总结

Steenhuis, E.G.M., Schoenaker, I.J.H., de Groot, J.W.B., Fiebrich, H.B., de Graaf, J.C., Brohet, R.M., van Dijk, J.D., van Westreenen, H.L., Siersema, P.D., de Vos tot Nederveen Cappel, W.H. (2020). Feasibility of volatile organic compound in breath analysis in the follow-up of colorectal cancer: A pilot study. European Journal of Surgical Oncology, 46(11), 2068-2073

研究设计

研究类型
Observational

入排标准

入选标准

  • 1. Follow-up patients with an intentional curative treatment of CRC stage I to IV
  • a CRC treated with curative intent by means of a colorectal resection
  • curative treatment of synchronous metastases in combination with colorectal resection
  • curatively treated metachronous metastases, after colorectal resection
  • 2. Age = 18 years.

排除标准

  • 1. Not proficient in Dutch
  • 2. Reason to believe that the patient cannot perform a breath test
  • 3. CRC not treated curatively
  • 4. CRC pT1N0Mx / pT1NxMx (patients receiving endoscopic control only)
  • 5. Local (surgical or endoscopic) resection
  • 6. Active treatment of other malignancies within the past three months

研究者

发起方
•The ‘Medisch Specialistisch Bedrijf’(MSB) of Isala has invested in The eNose Company, Zutphen, The Netherlands. The researchers have received a grant from the Innovation & Science fund Isala. •The eNose Company invests by making the eNose devices, disposable mouthpieces and analysis of the breath tests available.

相似试验